PiotrowskaZIsozakiHLennerzJK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529-1539. doi:10.1158/2159-8290
KlempnerSJBazhenovaLABraitehFS, et al. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 2015;89:357-359. doi:10.1016/j.lungcan.2015.06.021
4.
StinchcombeTE.Current management of RET rearranged non-small cell lung cancer. Ther Adv Med Oncol. 2020;12:1758835920928634. doi:10.1177/1758835920928634
5.
DrilonAOxnardGRTanDSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383:813-824. doi:10.1056/NEJMoa2005653
6.
RotowJPatelJHanleyM, et al. Combination osimertinib plus selpercatinib for EGFR-mutant non-small cell lung cancer (NSCLC) with acquired RET fusions. J Thorac Oncol. 2021;16(3 suppl):S230. doi:10.1016/j.jtho.2021.01.150
